Ann: Final Phase IIb AIPAC clinical trial results for Efti in MBC, page-38

A few years ago a great clinical stage (P2) Aussie biotech sold out to major BP at a significant discount to its 'intrinsic value' after its SP was cleverly driven down in a concerted effort by 'smart money'.

BP picked up a bargain - long term SH's were just pleased to get out with a modest return after months/year or so of SP being dumped - on the back of great clinical data.

I'm smelling the same game being played with Immutep.

Clinical data success = BP (our customers) want in at the lowest cost - eventually. Drive down SP - frustrate SH's and opportunity to go in for the 'kill'.

The only way to bypass this (limited potential customers -2 or 3 BP) is to go it alone - solo and be prepared to go all the way to drug commercialisation and sale of product.

If this strategy is clearly articulated by Marc - basically saying F'U big pharma, then I'm in.
But IMO Marc is hedging his bets which could end up with the worst of both worlds.